Clinical Trial

Entecavir to TAF Switch

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 25, 2020 (before its estimated August 15, 2020 completion). Its status may not reflect the trial's current state.
Summary
A research study to observe the safety, efficacy and tolerability of switching from Entecavir (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2018-04-03; most recent amendment 2022-05-13.
Status change: Active, Not Recruiting → Completed 2021-10-18
Status change: Recruiting → Active, Not Recruiting 2019-04-09
Trial Details
NCT Number NCT03489239
Lead Sponsor Thomas Jefferson University
Collaborators: Gilead Sciences
Conditions Hepatitis B
Enrollment 27 participants
Start Date 2017-11-16
Primary Completion 2020-08-15 (estimated)
Study Completion 2020-09-16 (estimated)
Updated on ClinicalTrials.gov 2020-06-25